Patents by Inventor Robert E. Reiter

Robert E. Reiter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF
    Publication number: 20240026025
    Abstract: This invention relates to inhibition of the N-cadherin signaling using a humanized anti-N-cadherin antibody. In one embodiment, the invention relates to methods of treating an N-cadherin-mediated disease or N-cadherin-mediated disorder in a subject by contacting the subject with an anti-N-cadherin antibody.
    Type: Application
    Filed: June 8, 2023
    Publication date: January 25, 2024
    Inventors: Kirstin A. Zettlitz, Anna M. Wu, Robert E. Reiter
  • ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF
    Publication number: 20230181772
    Abstract: Disclosed are engineered anti-prostate stem cell antigen (PSCA) fusion proteins and uses thereof to detect and treat cancers expressing PSCA.
    Type: Application
    Filed: May 18, 2021
    Publication date: June 15, 2023
    Applicants: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. WU, Kirstin A. ZETTLITZ, Robert E. REITER
  • HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF
    Publication number: 20200165351
    Abstract: This invention relates to inhibition of the N-cadherin signaling using a humanized anti-N-cadherin antibody. In one embodiment, the invention relates to methods of treating an N-cadherin-mediated disease or N-cadherin-mediated disorder in a subject by contacting the subject with an anti-N-cadherin antibody.
    Type: Application
    Filed: June 6, 2018
    Publication date: May 28, 2020
    Inventors: Kirstin A. Zettlitz, Anna M. Wu, Robert E. Reiter
  • High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
    Patent number: 9527919
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 27, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF
    Publication number: 20160347855
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 1, 2016
    Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
  • N-cadherin: target for cancer diagnosis and therapy
    Patent number: 9470689
    Abstract: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: October 18, 2016
    Assignee: The Regents of the University of California
    Inventor: Robert E. Reiter
  • Antibodies against cancer target block tumor growth, angiogenesis and metastatis
    Patent number: 9388247
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: July 12, 2016
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Zev Wainberg
  • HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION
    Publication number: 20150239983
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Application
    Filed: December 5, 2014
    Publication date: August 27, 2015
    Inventors: Anna M. WU, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis and Metastatis
    Publication number: 20150175706
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 25, 2015
    Inventors: Robert E. Reiter, Zev Wainberg
  • Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
    Patent number: 8940871
    Abstract: The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter
  • High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
    Patent number: 8940298
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF
    Publication number: 20140364591
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
  • N-Cadherin: Target for Cancer Diagnosis and Therapy
    Publication number: 20140220005
    Abstract: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.
    Type: Application
    Filed: December 31, 2013
    Publication date: August 7, 2014
    Applicant: The Regents of the University of California
    Inventor: Robert E. Reiter
  • PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia
    Patent number: 8759006
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: June 24, 2014
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • Fully human antibodies against N-cadherin
    Patent number: 8703920
    Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: April 22, 2014
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
  • N-cadherin: target for cancer diagnosis and therapy
    Patent number: 8663635
    Abstract: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: March 4, 2014
    Assignee: The Regents of the University of California
    Inventor: Robert E. Reiter
  • Fully Human Antibodies Against N-Cadherin
    Publication number: 20140017240
    Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
    Type: Application
    Filed: June 17, 2013
    Publication date: January 16, 2014
    Applicant: The Regents of the University of California
    Inventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
  • GENE EXPRESSION IN N-CADHERIN OVEREXPRESSING PROSTATE CANCERS AND THEIR CONTROLS
    Publication number: 20130274128
    Abstract: The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin.
    Type: Application
    Filed: September 20, 2011
    Publication date: October 17, 2013
    Applicant: The Regents of the University of Califorina
    Inventor: Robert E. Reiter
  • PSCA: prostate stem cell antigen and uses thereof
    Patent number: 8524460
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: September 3, 2013
    Assignee: The Regents of the University
    Inventors: Robert E. Reiter, Owen N. Witte
  • NOVEL DIAGNOSTIC AND THERAPEUTIC TARGETS ASSOCIATED WITH OR REGULATED BY N-CADHERIN EXPRESSION AND/OR EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) IN PROSTATE CANCER AND OTHER MALIGNANCIES
    Publication number: 20130137584
    Abstract: The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin.
    Type: Application
    Filed: February 1, 2011
    Publication date: May 30, 2013
    Applicant: The Regents of the University of California
    Inventor: Robert E. Reiter